Yang Quan Shi

Researchers are evaluating the efficacy and safety of Antiwei granules for treating the common cold, specifically the wind-cold syndrome type. This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to assess how well Antiwei granules work and how safe they are for adults aged 18 to 65 who have had a recent onset of the common cold. Participants will be randomly assigned to receive either Antiwei granules or a placebo. Both groups will take oral doses of 1 sack (6g) three times daily for a total of 9 sacks over a 3-day treatment period. The study compares the effects of the active granules versus placebo on cold symptoms. During the trial, participants will be monitored closely with assessments focusing on the cure rate after 3 days of treatment. Researchers will track symptoms and safety throughout the short treatment period. The total study duration for each participant is about 3 days, during which the effectiveness and any side effects of the treatment will be recorded and analyzed.

Researchers are evaluating the immune response and safety of a new 24-valent pneumococcal polysaccharide conjugate vaccine (RZ700) in infants and young children aged from 2 months (minimum 6 weeks) to 71 months. This Phase II clinical trial aims to compare this vaccine's effects with an existing 13-valent pneumococcal vaccine (Prevnar 13) to better protect against pneumococcal infectious disease. Participants will receive doses of either the 24-valent vaccine or the 13-valent vaccine, each supplied in a 0.5 ml prefilled syringe. The 24-valent vaccine targets 24 pneumococcal serotypes, while the 13-valent vaccine targets 13 serotypes. The study includes both primary and booster immunizations, given according to the trial schedule. During the trial, children will be monitored for their immune response by measuring specific antibody levels 30 days after the primary and booster doses. Researchers will also assess safety by observing any reactions or adverse events. Guardians will provide consent and participate in visits and assessments throughout the study, which covers the vaccination period and follow-up evaluations to ensure thorough monitoring.

Researchers are evaluating the efficacy and safety of TQC2731 injection in adults with severe asthma that is not well controlled. This is a Phase III, multicenter, randomized, double-blind, placebo-controlled trial involving 660 participants aged 18 to 75 years. The study focuses on those who have had asthma diagnosed for at least a year and have experienced multiple asthma exacerbations in the past year despite using high-dose inhaled corticosteroids and other asthma medications. Participants are randomly assigned in equal numbers to receive either TQC2731 injection at a dose of 420 mg every four weeks or a placebo injection with no active drug. Both treatments are given by subcutaneous injection. The study treatment lasts for 52 weeks, during which the effects of blocking the Thymic Stromal Lymphopoietin (TSLP) protein by TQC2731 are assessed. Throughout the study, participants will be monitored for asthma exacerbations and other health outcomes. Researchers will regularly evaluate safety and treatment effects over the full 52-week period. The primary outcome measured is the annual rate of asthma exacerbations from the first day of dosing through completion. Participants' medication use, symptom control, and adverse events will also be tracked to assess treatment impact and safety.